We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Companies hope for kinase inhibitor JAKpot.
- Authors
Dolgin, Elie
- Abstract
The article focuses on the prospects of Janus kinase 2 (JAK2) inhibitors in the treatment of various diseases including myelofibrosis, polycythaemia vera and essential thrombocytopenia. It highlights the drug ruxolitinib from Incyte Pharmaceuticals Inc. which was reviewed by the U.S. Food and Drug Administration (FDA) in August 2011. It emphasizes the LY2784544 JAK2 inhibitor from Eli Lilly & Co. which is 40 times more active than the wild-type kinase.
- Subjects
UNITED States; DRUG development; INCYTE Corp.; UNITED States. Food &; Drug Administration; ELI Lilly &; Co.
- Publication
Nature Reviews Drug Discovery, 2011, Vol 10, Issue 10, p717
- ISSN
1474-1776
- Publication type
journal article
- DOI
10.1038/nrd3571